Which topical microbicides for blocking HIV-1 transmission will work in the real world?
about
Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections.Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent.Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.Homeostatic properties of Lactobacillus jensenii engineered as a live vaginal anti-HIV microbicideGlycerol monolaurate prevents mucosal SIV transmissionEffective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaquesLiposomes for HIV prophylaxis.Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaquesA nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249.Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.HIV-1 Nef: at the crossroadsHighly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.Animal models for microbicide studies.Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.Unbiased proteomics analysis demonstrates significant variability in mucosal immune factor expression depending on the site and method of collectionHuman immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection.Transport theory for HIV diffusion through in vivo distributions of topical microbicide gels.Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors.Specific microbicides in the prevention of HIV infection.Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.Turing patterns from dynamics of early HIV infection.Vaginal Mucosa and Drug Delivery
P2860
Q30359545-EE6A7EB2-442C-4AFE-A3CA-D8B80DDEF207Q33962742-EFC99D57-497F-4F28-9B91-0EA35439D904Q34057568-8C26EF14-0D1C-4011-BF4B-40BE36A2AB6AQ34150951-6E2C013E-2476-44F6-A189-5D9D94606754Q34539354-2ED89238-45BE-48FB-8089-BD5CE3E4368BQ34957016-ECA192F5-9C64-4BFB-BACB-F2B0FAC50106Q35101333-046C5FED-86FD-4A84-B2B2-6B1F8F33FB6DQ35686901-CDB0E1D5-069F-4E51-8D33-6962418D0FFEQ35941408-7898D252-423F-4B8C-8D0A-9933138F2AF6Q36023146-3653F27B-F274-4881-AC53-CDC7CDB4962CQ36113575-4CCD6433-342C-4C83-923B-87CC8FA8EA4CQ36173759-4147FD56-ED31-4153-9D82-7691F9921B02Q36296739-29B8033C-77B8-4C84-ABA0-631B54116A31Q36364164-AC0F9890-006D-4132-AE9C-F4B39A40D21CQ36414891-9857F1F0-1CC8-4785-BF71-BE7F988CB110Q36802500-61AFBF8C-5EC7-412F-901E-37919DB1402DQ36840299-89E4D6E9-0EA0-4E9A-B7F8-635F172159A1Q36926697-C1C40169-1933-4A6E-9208-92D5A3AB0FD8Q36976659-1962E9F6-30A5-498D-9469-D1DE7CF966E6Q37017688-FF84086A-70EA-4FA5-8694-667016AE8B1FQ37025857-1F2FBDB0-3D47-4E88-B90D-070785DEE98FQ37088591-C7926812-14C3-42C0-A2D8-B2AE9AFFAFE5Q37309287-48A8D6D0-95D8-4D0B-9BD8-7F891A9996DBQ37333928-ECBCD90B-2E95-40CD-A900-C7636E5D1DA1Q37405990-68E23FC6-F267-4C43-B7AA-18F785651E33Q37410434-6A1CDF89-3C88-458D-AF72-F726D9FB8D78Q37421895-8C8DB97A-FD35-4D6F-8613-AD817EDC1863Q37855900-07E8D5D0-4D24-4DC0-9E62-7CAA7F52E33EQ37932048-7E7BD7CD-9560-4432-B978-8E9457149705Q38574172-29390136-D700-486B-A9D5-DD698EA3D03BQ51237698-78EEB8D3-0A83-4187-89C4-6A1469B516A9Q57570821-F7FE00CD-48BB-4C1E-BFE7-B271A4208A56
P2860
Which topical microbicides for blocking HIV-1 transmission will work in the real world?
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Which topical microbicides for blocking HIV-1 transmission will work in the real world?
@ast
Which topical microbicides for blocking HIV-1 transmission will work in the real world?
@en
type
label
Which topical microbicides for blocking HIV-1 transmission will work in the real world?
@ast
Which topical microbicides for blocking HIV-1 transmission will work in the real world?
@en
prefLabel
Which topical microbicides for blocking HIV-1 transmission will work in the real world?
@ast
Which topical microbicides for blocking HIV-1 transmission will work in the real world?
@en
P2860
P921
P1433
P1476
Which topical microbicides for blocking HIV-1 transmission will work in the real world?
@en
P2093
John P Moore
Per Johan Klasse
P2860
P356
10.1371/JOURNAL.PMED.0030351
P407
P5008
P577
2006-09-01T00:00:00Z